Asian American Medical Group Ltd
ASX:AJJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (18.2), the stock would be worth AU$-0.06 (258% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -11.5 | AU$0.04 |
0%
|
| Industry Average | 18.2 | AU$-0.06 |
-258%
|
| Country Average | 18.2 | AU$-0.06 |
-258%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| SG |
|
Asian American Medical Group Ltd
ASX:AJJ
|
14.5m AUD | -11.5 | 695.2 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
106.6B USD | 20.1 | 60.3 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
71B EUR | 12.4 | 13.7 | |
| US |
|
Cigna Corp
NYSE:CI
|
77B USD | 0 | 12.9 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.3B EUR | 29.9 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.5B EUR | 16.6 | 22.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21B USD | 19.4 | 20.6 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.1B USD | 21.2 | 24.1 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.6B EUR | 9.9 | 10.9 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | -48.9 | -26.2 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 15 | 14 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 18.2 |
| 70th Percentile | 32.2 |
| Max | 15 154.9 |
Other Multiples
Asian American Medical Group Ltd
Glance View
Asian American Medical Group Ltd. provides healthcare consultancy and management services. The firm's segments include liver, Multi-Specialty, Healthcare Management and Consultancy, and Healthcare Real Estate. The liver segment operates is engaged in the business of treatment of all liver, pancreas and bile duct diseases in adults and children. The Multi-Specialty segment is a medical specialist in Singapore and abroad, mainly in the United States and Great Britain. The Multi-Specialty, Healthcare Management and Consultancy segment is focused on sourcing and identifying potential healthcare-related projects. THe Healthcare Real Estate segment is managed under the Company’s subsidiary Asian American Healthcare Ventures Pte Ltd (AAHV).
